Skip to main content
BioInfra Life Science Inc. logo

BioInfra Life Science Inc. — Investor Relations & Filings

Ticker · 266470 ISIN · KR7266470004 KO Professional, scientific and technical activities
Open in API
Filings indexed 121 across all filing types
Latest filing 2020-07-29 Major Shareholding Noti…
Country KR South Korea
Listing KO 266470

About BioInfra Life Science Inc.

http://bioinfra.co.kr/?lang=en

BioInfra Life Science Inc. is a biotechnology company focused on cancer prevention, early detection, and treatment. The company's core technology is a multi-biomarker blood test, an in-vitro diagnostic solution designed for the early screening of eight major cancers, including lung, liver, stomach, colorectal, prostate, breast, pancreatic, and ovarian cancer. This test analyzes cancer risk from a small blood sample. In addition to its diagnostic platform, the company develops cancer gene treatments and technologies to monitor the potential for metastasis and recurrence, aiming to provide innovative solutions in the healthcare field.

Recent filings

Filing Released Lang Actions
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is a 'Report of Large Shareholding' (주식등의 대량보유상황보고서) filed under the Capital Markets Act in South Korea. This type of filing is used to disclose significant ownership stakes (typically 5% or more) in a company, often referred to as a 'Major Shareholding Notification'. The document details the reporting person (Kim Chul-woo), special related parties, their shareholding percentages, and the purpose of holding (management influence). It does not fit into other categories like Director's Dealing (which is for individual trades) or Share Issue (which is for the company's capital changes), but rather specifically tracks the concentration of ownership.
2020-07-29 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is a standard Korean regulatory filing titled '임원ㆍ주요주주 특정증권등 소유상황보고서' (Report on Ownership of Specific Securities by Executives and Major Shareholders). This document details the share ownership and changes in holdings by a company executive (Kim Chul-woo) of Bioinfra Life Science. In the context of financial filings, reports detailing personal share transactions by company directors and executives are classified as 'Director's Dealing'.
2020-07-29 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed with the Korean financial authorities. This type of filing is specifically used to disclose share ownership changes by company insiders (directors/executives). In the provided classification schema, this corresponds to 'Director's Dealing' (DIRS), which covers personal share transactions and ownership status reports by company directors and executives.
2020-07-29 Korean
[기재정정]주요사항보고서(유상증자결정)
Share Issue/Capital Change Classification · 95% confidence The document is a 'Major Matter Report' (주요사항보고서) regarding a capital increase (유상증자결정) for Bioinfra Life Science. It details the issuance of new shares, specifically redeemable convertible preferred shares, including conversion ratios, redemption terms, and third-party allocation details. This type of filing is a formal regulatory disclosure of a capital structure change and issuance of new shares, which falls under the 'Share Issue/Capital Change' category.
2020-05-20 Korean
[기재정정]사업보고서 (2018.12)
Audit Report / Information Classification · 98% confidence The document is a formal 'Correction Report' (정정신고) for a previously submitted 'Business Report' (사업보고서), which is the Korean equivalent of a 10-K. It details specific amendments to financial statements, management information, and shareholding data. Since it is a correction to an existing annual report rather than the initial filing itself, and it contains detailed financial and operational data, it is classified as an Annual Report (10-K) under the context of regulatory filings. FY 2018
2020-05-19 Korean
[기재정정]사업보고서 (2019.12)
Annual Report Classification · 100% confidence The document is a 'Correction Report' (정정신고) for an 'Annual Report' (사업보고서) originally submitted on March 30, 2020. It details specific amendments to sections such as 'Company Overview', 'Management Changes', 'Convertible Bond Issuance', and 'Shareholding Status'. Since this is a formal amendment to a previously filed Annual Report, it falls under the category of an Annual Report (10-K) filing, as it constitutes the official yearly reporting documentation for the company. FY 2019
2020-05-19 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.